Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Stephen Padilla, 4 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 3 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.

Squamous cell carcinoma of the bladder does not promote high-risk HPV

31 Jul 2020

High-risk human papilloma virus (HPV) infection occurs rarely in patients with squamous cell carcinoma (SCC) of the bladder, despite having an aggressive histologic subtype, a study has found.

Researchers looked at 207 patients with SCCs of the bladder (mean age at the time of diagnosis, 66 years; 43.5 percent female). Of these patients, 133 (64.3 percent) had a smoking history and 83 (40.1 percent) had medical conditions leading to chronic bladder irritation such as stones, indwelling catheters, and chronic urinary tract infection. None had a history of Schistosoma infection.

The majority (75 percent) of patients presented with a higher-stage (>pT2) disease at the time of cystectomy. Mean tumour size was 5.6 cm, and 36 (17 percent) patients had lymph node positive disease.

Of the 204 patients included in the p16 IHC and high-risk HPV ISH analyses, 52 (25 percent) exhibited diffuse p16 expression and only a single patient (0.5 percent) had high-risk HPV.

Over a mean follow-up of 4.6 years, 76 patients (36.7 percent) had disease recurrence and 90 (43.5 percent) died from SCC of the bladder. The mean overall survival was 9.52 years, time-to cancer-specific mortality was 17.0 years, and recurrence-free survival was 8.70 years.

Significant predictors of cancer-specific mortality were tumour size (hazard ratio [HR], 1.23), number of lymph nodes removed (HR, 0.98), number of positive lymph nodes (HR, 1.28), and perineural invasion (HR, 2.19).

In genital and oral cancers, high-risk HPV has been linked to the overexpression of the p16 protein, the researchers noted. However, this does not appear to be the case for bladder cancer, specifically SCC. This discrepancy may be explained by cross contamination of close regional HPV-driven SCCs in previous studies.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Stephen Padilla, 4 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 3 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.